Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell, Marginal Zone

Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.

645 public trials 88 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell, Marginal Zone trial results

Completed

Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

NCT00278408

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +21 more
Locations
  • Rigshospitalet, Department of Hematology Copenhagen, Denmark
  • Amtssygehuset i Herlev Herlev, Denmark
  • GMP Tummes/Weinberg Aachen, Germany
  • Klinikum St. Marien Amberg, Germany
View all 152 locations
View Trial Details
Completed

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

NCT03424122

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • University of Arizona Cancer Center - Out Pt. Tucson, Arizona, United States
  • Indiana Blood and Marrow Transplantation Indianapolis, Indiana, United States
  • Comprehensive Cancer Center of Nevada Las Vegas, Nevada, United States
  • Texas Oncology Austin, Texas, United States
View all 21 locations
View Trial Details
Completed

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

NCT03144674

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University of Alabama At Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States
  • Arizona Oncology Associates Tempe, Arizona, United States
  • Torrance Health Association Redondo Beach, California, United States
  • Sansum Clinic Santa Barbara, California, United States
View all 86 locations
View Trial Details
Completed

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

NCT01996865

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Local Institution - 055 Tucson, Arizona, United States
  • Local Institution - 077 Little Rock, Arkansas, United States
  • Local Institution - 079 Berkeley, California, United States
  • Local Institution - 142 Concord, California, United States
View all 126 locations
View Trial Details
Completed

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

NCT03133221

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +34 more
Locations
  • University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Greenebaum Cancer Center at University of Maryland Medical Center Baltimore, Maryland, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

NCT01974440

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Gilbert, Arizona, United States
  • Campbell, California, United States
  • Duarte, California, United States
  • La Jolla, California, United States
View all 135 locations
View Trial Details

Related conditions